Global life expectancy rebounded in 2022 after a two-year decline, though it has yet to recover to its 2019 peak, according to the latest data from the World Bank.

Growth is expected to be supported by ENHERTU's continued expansion. Profit attributable to owners of the company for FY2024 was revised upward by ¥15 billion to ¥240 billion, driven by improved ...

Life insurance can protect your loved ones when you're gone by replacing lost income, paying off debts or leaving a financial legacy. There's a lot to consider, though, with different providers ...

Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. HER2 is a receptor protein that accelerates the growth of cancer cells.

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. East Asian Americans are ...

She is passionate about empowering others to protect life's most important assets. Wh... Amy Danise is the managing editor for the insurance section at Forbes Advisor, which encompasses auto ...

1. Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu. Roche. News release. January 31 ...

Having COPD lowers your life expectancy. However, the amount that it affects your life expectancy depends on many factors, such as how far your COPD has progressed and whether you quit smoking or ...

NEW YORK – Roche announced on Friday that its Pathway Anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody has received a label expansion from the US Food and Drug Administration as a companion ...

(Bassett, 1/29) MedPage Today: FDA Expands Enhertu Approval To HER2-Ultralow Breast Cancer ... (Monaco, 1/29) Axios: Racial Gaps In Life Expectancy Shrank Before COVID The gap in average life ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...